ASCO 2024 | Emerging therapies in gynecologic oncology at ASCO 2024
Frederik Marmé, MD, PhD, University of Heidelberg, Germany, discusses the results presented from studies investigating gynecological cancers. In gynecologic oncology, dual checkpoint inhibitors, particularly the combination of ipilimumab and nivolumab, has shown promising results in clear cell gynecological cancers, including ovarian, endometrial, and cervical cancers. A randomized study demonstrated that this combination therapy significantly improved response rates compared to single-agent strategies. Another study focusing on pembrolizumab and an anti-TIGIT antibody in mismatch repair-deficient endometrial cancer reported response rates in over half of the patients studied. The need for further investigation is highlighted, suggesting the exploration of their effects in combination with chemotherapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AGENDIA; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role – Amgen; AstraZeneca (Inst); Clovis Oncology; CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Seagen; Seagen; Vaccibody (Inst)
Research Funding – AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses – AstraZeneca; Gilead Sciences; Pfizer; Roche
